Phase 3 Neuroendocrine Tumors Clinical Trials
7 recruitingPhase 3
What is a Phase 3 trial?
Phase 3 trials compare the new treatment against the current standard of care in large groups, often hundreds to thousands of participants. Successful Phase 3 results are typically required for regulatory approval.
Showing 1–7 of 7 trials
Recruiting
Phase 2Phase 3
Sirolimus for Injection (Albumin Bound) Combined With Octreotide Long-acting Injection in Patients With Metastatic Gastroenteropancreatic Neuroendocrine Tumors
Gastroenteropancreatic Neuroendocrine Tumors
CSPC ZhongQi Pharmaceutical Technology Co., Ltd.298 enrolled1 locationNCT07165886
Recruiting
Phase 3
Efficacy and Safety of Radiotherapy Compared to Everolimus in Somatostatin Receptor Positive Neuroendocrine Tumors of the Lung and Thymus.
Neuroendocrine TumorsLung Neuroendocrine NeoplasmThymus Neoplasms
Grupo Espanol de Tumores Neuroendocrinos120 enrolled27 locationsNCT05918302
Recruiting
Phase 3
18F-DOPA II - PET Imaging Optimization
Neuroendocrine TumorsBrain TumorNeuroblastoma+3 more
University of Alberta800 enrolled1 locationNCT04706910
Recruiting
Phase 3
Systemic Targeted Adaptive RadioTherapy of NeuroEndocrine Tumors.
Neuroendocrine Tumors
Lund University Hospital300 enrolled4 locationsNCT05387603
Recruiting
Phase 3
Randomized Interval Assessment Trial of Lu177-Dotatate in Slowly Progressive G1-2 Advanced Midgut Neuroendocrine Tumors
Grade1-2 Advanced Midgut Neuroendocrine Tumors (NETs)
Grupo Espanol de Tumores Neuroendocrinos166 enrolled21 locationsNCT06878664
Recruiting
Phase 2Phase 3
Absorbed Tumor Dose in Peptide Receptor Radionuclide Therapy with Long-acting Somatostatin Analogues - ATSA Trial
Neuroendocrine NeoplasmNeuroendocrine TumorsNeuroendocrine Tumor Grade 1+1 more
The Netherlands Cancer Institute39 enrolled1 locationNCT06855095
Recruiting
Phase 3
68Ga-DOTA-TATE PET/CT Imaging in NETs
Neuroendocrine Tumors
Centre de recherche du Centre hospitalier universitaire de Sherbrooke5,000 enrolled2 locationsNCT04847505